169 related articles for article (PubMed ID: 37721580)
21. Prognostic Impact of 18F-FDG PET/CT in Patients With Aggressive B-Cell Lymphoma Treated With Anti-CD19 Chimeric Antigen Receptor T Cells.
Sesques P; Tordo J; Ferrant E; Safar V; Wallet F; Dhomps A; Brisou G; Bouafia F; Karlin L; Ghergus D; Golfier C; Lequeu H; Lazareth A; Vercasson M; Hospital-Gustem C; Schwiertz V; Choquet M; Sujobert P; Novelli S; Mialou V; Hequet O; Carras S; Fouillet L; Lebras L; Guillermin Y; Leyronnas C; Cavalieri D; Janier M; Ghesquières H; Salles G; Bachy E
Clin Nucl Med; 2021 Aug; 46(8):627-634. PubMed ID: 34115706
[TBL] [Abstract][Full Text] [Related]
22. Baseline Total Metabolic Tumor Volume and Total Lesion Glycolysis Measured on 18F-FDG PET-CT Predict Outcomes in T-Cell Lymphoblastic Lymphoma.
Feng X; Wen X; Li L; Sun Z; Li X; Zhang L; Wu J; Fu X; Wang X; Yu H; Ma X; Zhang X; Xie X; Han X; Zhang M
Cancer Res Treat; 2021 Jul; 53(3):837-846. PubMed ID: 33285054
[TBL] [Abstract][Full Text] [Related]
23. Combination of baseline FDG PET/CT total metabolic tumour volume and gene expression profile have a robust predictive value in patients with diffuse large B-cell lymphoma.
Toledano MN; Desbordes P; Banjar A; Gardin I; Vera P; Ruminy P; Jardin F; Tilly H; Becker S
Eur J Nucl Med Mol Imaging; 2018 May; 45(5):680-688. PubMed ID: 29344718
[TBL] [Abstract][Full Text] [Related]
24. Prognostic value of the metabolic bulk volume in patients with diffuse large B-cell lymphoma on baseline
Delaby G; Hubaut MA; Morschhauser F; Besson A; Huglo D; Herbaux C; Baillet C
Leuk Lymphoma; 2020 Jul; 61(7):1584-1591. PubMed ID: 32100597
[TBL] [Abstract][Full Text] [Related]
25. Prognostic value of baseline and early response FDG-PET/CT in patients with refractory and relapsed aggressive B-cell lymphoma undergoing CAR-T cell therapy.
Georgi TW; Kurch L; Franke GN; Jentzsch M; Schwind S; Perez-Fernandez C; Petermann N; Merz M; Metzeler K; Borte G; Hoffmann S; Herling M; Denecke T; Kluge R; Sabri O; Platzbecker U; Vučinić V
J Cancer Res Clin Oncol; 2023 Aug; 149(9):6131-6138. PubMed ID: 36662305
[TBL] [Abstract][Full Text] [Related]
26. Metabolic tumor volume predicts outcome in patients with advanced stage follicular lymphoma from the RELEVANCE trial.
Cottereau AS; Rebaud L; Trotman J; Feugier P; Nastoupil LJ; Bachy E; Flinn IW; Haioun C; Ysebaert L; Bartlett NL; Tilly H; Casasnovas O; Ricci R; Portugues C; Buvat I; Meignan M; Morschhauser F
Ann Oncol; 2024 Jan; 35(1):130-137. PubMed ID: 37898239
[TBL] [Abstract][Full Text] [Related]
27. Predictive value of Dmax and %ΔSUVmax of
Dang J; Peng X; Wu P; Yao Y; Tan X; Ye Z; Jiang X; Jiang X; Liu Y; Chen S; Cheng Z
BMC Med Imaging; 2023 Oct; 23(1):173. PubMed ID: 37907837
[TBL] [Abstract][Full Text] [Related]
28.
Derlin T; Schultze-Florey C; Werner RA; Möhn N; Skripuletz T; David S; Beutel G; Eder M; Ross TL; Bengel FM; Ganser A; Koenecke C
Ann Nucl Med; 2021 Jan; 35(1):132-138. PubMed ID: 33174144
[TBL] [Abstract][Full Text] [Related]
29. Development of a radiomic-clinical nomogram for prediction of survival in patients with diffuse large B-cell lymphoma treated with chimeric antigen receptor T cells.
Zhou Y; Zhang B; Han J; Dai N; Jia T; Huang H; Deng S; Sang S
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11549-11560. PubMed ID: 37395846
[TBL] [Abstract][Full Text] [Related]
30. Prognostic value of baseline
Zhou Y; Hong Z; Zhou M; Sang S; Zhang B; Li J; Li Q; Wu Y; Deng S
J Med Imaging Radiat Oncol; 2020 Feb; 64(1):87-95. PubMed ID: 31880103
[TBL] [Abstract][Full Text] [Related]
31. Immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy for lymphoma: predictive biomarkers and clinical outcomes.
Holtzman NG; Xie H; Bentzen S; Kesari V; Bukhari A; El Chaer F; Lutfi F; Siglin J; Hutnick E; Gahres N; Ruehle K; Ahmad H; Shanholtz C; Kocoglu MH; Badros AZ; Yared JA; Hardy NM; Rapoport AP; Dahiya S
Neuro Oncol; 2021 Jan; 23(1):112-121. PubMed ID: 32750704
[TBL] [Abstract][Full Text] [Related]
32. Prognostic role of baseline
Albano D; Bosio G; Camoni L; Farina M; Re A; Tucci A; Giubbini R; Bertagna F
Hematol Oncol; 2019 Feb; 37(1):39-46. PubMed ID: 30299563
[TBL] [Abstract][Full Text] [Related]
33. A nomogram for predicting the rapid progression of diffuse large B-cell lymphoma established by combining baseline PET/CT total metabolic tumor volume, lesion diffusion, and TP53 mutations.
Liu C; Shi P; Li Z; Li B; Li Z
Cancer Med; 2023 Aug; 12(16):16734-16743. PubMed ID: 37366281
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of the prognostic value of different methods of calculating the tumour metabolic volume with
Guzmán Ortiz S; Mucientes Rasilla J; Vargas Núñez JA; Royuela A; Navarro Matilla B; Mitjavila Casanovas M
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(6):340-346. PubMed ID: 32646783
[TBL] [Abstract][Full Text] [Related]
35. Prognostic value of total lesion glycolysis of baseline 18F-fluorodeoxyglucose positron emission tomography/computed tomography in diffuse large B-cell lymphoma.
Zhou M; Chen Y; Huang H; Zhou X; Liu J; Huang G
Oncotarget; 2016 Dec; 7(50):83544-83553. PubMed ID: 27835875
[TBL] [Abstract][Full Text] [Related]
36. Role of Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Predicting the Adverse Effects of Chimeric Antigen Receptor T Cell Therapy in Patients with Non-Hodgkin Lymphoma.
Wang J; Hu Y; Yang S; Wei G; Zhao X; Wu W; Zhang Y; Zhang Y; Chen D; Wu Z; Xiao L; Chang AH; Huang H; Zhao K
Biol Blood Marrow Transplant; 2019 Jun; 25(6):1092-1098. PubMed ID: 30769193
[TBL] [Abstract][Full Text] [Related]
37. [Prognostic value of pretreatment (18)F-FDG PET-CT for patients with advanced diffuse large B-cell lymphoma].
Ding CY; Guo Z; Sun J; Yang WP; Li TR
Zhonghua Zhong Liu Za Zhi; 2018 Jul; 40(7):528-533. PubMed ID: 30060362
[No Abstract] [Full Text] [Related]
38. [Diagnostic and Prognostic Value of
Chen X; Qiao WL; Song JH; Liu CC; Han L; Wu S; Zhao JH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Aug; 31(4):1044-1049. PubMed ID: 37551475
[TBL] [Abstract][Full Text] [Related]
39. Molecular Profile and FDG-PET/CT Total Metabolic Tumor Volume Improve Risk Classification at Diagnosis for Patients with Diffuse Large B-Cell Lymphoma.
Cottereau AS; Lanic H; Mareschal S; Meignan M; Vera P; Tilly H; Jardin F; Becker S
Clin Cancer Res; 2016 Aug; 22(15):3801-9. PubMed ID: 26936916
[TBL] [Abstract][Full Text] [Related]
40. Outcomes of CD19-Directed Chimeric Antigen Receptor T Cell Therapy for Transformed Nonfollicular Lymphoma.
Dong N; Rubio Lopes-Garcia L; Viñal D; Bachmeier C; Shah BD; Nishihori T; Khimani F; Davila ML; Lazaryan A; Pinilla-Ibarz J; Locke FL; Jain MD; Chavez JC
Transplant Cell Ther; 2023 Jun; 29(6):349.e1-349.e8. PubMed ID: 36878427
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]